key: cord-0290150-ixu968fy authors: Jiang, Sheng; Wu, Shuting; Zhao, Gan; He, Yue; Guo, Xinrong; Zhang, Zhiyu; Hou, Jiawang; Ding, Yuan; Cheng, Alex; Wang, Bin title: Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein date: 2022-05-04 journal: bioRxiv DOI: 10.1101/2021.11.21.469172 sha: 732c7f32f9fb401d2f47ff818aaacf8250f6a8fc doc_id: 290150 cord_uid: ixu968fy The COVID-19 disease caused by infection with SARS-CoV-2 and its variants is devastating to the global public health and economy. To date, over a hundred COVID-19 vaccines are known to be under development and the few that have been approved to fight the disease are using the spike protein as the primary target antigen. Although virus neutralizing epitopes are mainly located within the RBD of the spike protein, the presence of T cell epitopes, particularly the CTL epitopes that are likely to be needed for killing infected cells, has received comparatively little attention. In this study, we predicted several potential T cell epitopes with web-based analytic tools, and narrowed them down from several potential MHC-I and MHC-II epitopes by ELIspot and cytolytic assays to a conserved MHC-I epitope. The epitope is highly conserved in current viral variants including the most recent Omicron and compatible with presentation by most HLA alleles worldwide. In conclusion, we identified a CTL epitope suitable for evaluating the CD8+ T cell-mediated cellular response and potentially for addition into future COVID-19 vaccine candidates to maximize CTL responses against SARS-CoV-2. (sFigure 1). Peptide 2 stimulated CD8+ T cells but not CD4+ cells, indicating that it can only be 1 3 5 presented by MHC-I ( Figure 3B ). To further investigate its sequence specificity, we mutated 1 3 6 several predicted anchor amino acids of peptide 2 according to the preferences of the H-2d MHC-I 1 3 7 allele [11] [12] [13] [14] . The mutated peptide 2 had a low MHC-I binding score in the IEDB prediction (Table 3) and TAP potential of peptide 2 on different HLA alleles by IEDB ( Figure 4D & Table 5 ). The allele (in Europe). These findings suggest that peptide 2 could be well recognized by the most 1 6 3 frequent HLA alleles of the worldwide population and can therefore be considered to be 1 6 4 promiscuous. In this study, we have defined and characterized a potential CTL epitope conserved and 1 6 7 established a BALB/c mice model to evaluate CTL responses to the spike protein of SARS-CoV-2. Furthermore, we found the peptide 2 may be well recognized by HLA alleles in most populations 1 6 9 worldwide. In recent studies, CD8+ T cell immunity was found to make major contributions to the 1 7 1 protective efficacy of SARS-CoV-2 vaccines [15] [16] [17] . Additionally, lymphopenia was more 1 7 2 accentuated in symptomatic COVID-19 patients with pneumonia than in those without pneumonia, 1 7 3 consistent with T cell immunity playing a protective role in pre-existing immunity against SARS- CoV-2 [17] [18] [19] . However, the role of T cell immunity in the pathology of COVID-19 has not been The SARS-CoV-2 virus was found to mutate rapidly, the development of vaccines that could 15 . We showed here that one particular peptide from the spike protein, peptide 1. The peptides covered the entire sequence of 258-512 amino acids in the spike protein; 2. The peptides were synthesized with an average 15 amino acid length and with nine amino acids overlapping each other. Notes: 1. MHC-I binding score was between 0 and 2. <0.5 strong binder, 0.5-2 weak binder, >2 non-binder. A high Immunogenicity score indicates that the degree of the peptide conformity to sequence preference was good. 3. The higher the TAP total score, the higher the likelihood that the peptide will be presented after being swallowed by DCs. 1. MHC-I binding score was between 0 and 2, where, the <0.5 represents a strong binder, 0.5-2 weak binder, >2 non-binder. 2. Underlined amino acids were the mutated residues in the Peptide 2 mut. Notes 4. MHC-I binding score was between 0 and 2. <0.5 strong binder, 0.5-2 weak binder, >2 non-binder. 5 . The high Immunogenicity score means the degree of the peptide conformity to sequence preference was good. The higher the TAP total score, the higher the likelihood that the peptide will be presented after being swallowed by DCs. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge Immunogenicity of a DNA vaccine candidate for COVID-19 A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes Identification of naturally processed peptides bound to the class I MHC molecule H-2Kd of normal and TAP-deficient cells H-2Dd exploits a four residue peptide binding motif Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans T cell immunity to SARS-CoV-2 following natural infection and vaccination Analysis of clinical characteristics and laboratory findings of 95 cases of China: a retrospective analysis COVID-19 immune signatures reveal stable antiviral T cell function despite 2 0 declining humoral responses Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses In vivo assessment of specific cytotoxic T lymphocyte killing